Verified Nov 2026
Other
·
Minneapolis, Minnesota
·
Since 2001
CVRx is a publicly listed medical device company headquartered in Minneapolis, Minnesota, founded in 2001 and traded on NASDAQ under the ticker CVRX. It employs between 200 and 500 people and serves the medical and health care sectors. Its flagship product, Barostim, is an implantable system that delivers electrical pulses to baroreceptors in the carotid artery to treat systolic heart failure and resistant hypertension. The company is currently enrolling patients in the BENEFIT-HF trial, which began first patient enrollment in May 2026.
CVRx | Barostim at a glance
Revenue
56.7M
Employees
200-500
Founded
2001
Headquarters
Minneapolis, Minnesota
Ownership
Publicly traded (NASDAQ: CVRX)
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Overview
CVRx is a publicly listed medical device company headquartered in Minneapolis, Minnesota, founded in 2001 and traded on NASDAQ under the ticker CVRX. It employs between 200 and 500 people and serves the medical and health care sectors. Its flagship product, Barostim, is an implantable system that delivers electrical pulses to baroreceptors in the carotid artery to treat systolic heart failure and resistant hypertension. The company is currently enrolling patients in the BENEFIT-HF trial, which began first patient enrollment in May 2026.
At a glance
Attribute | Detail |
|---|---|
Founded | 2001 |
Headquarters | Minneapolis, Minnesota |
Employees | 200-500 |
Revenue | 56.7M |
Ownership | Publicly traded (NASDAQ: CVRX) |
What CVRx | Barostim makes
Barostim is an implantable baroreflex activation therapy device that is approved in the United States and Europe.
Latest developments
2026-11-05 — CVRx Reports Third Quarter 2026 Financial and Operating (globenewswire.com)
2026-08-24 — CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy | CVRx (cvrx.com)
2026-08-06 — CVRx Reports Second Quarter 2026 Financial and Operating Results | CVRx (cvrx.com)
2026-05-04 — CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population | CVRx (cvrx.com)
2026-04-13 — CVRx Reports Preliminary First Quarter 2026 Financial Results | CVRx (cvrx.com)
2026-01-22 — CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population | CVRx (cvrx.com)
Company details
CVRx is a public company with an estimated annual revenue band of 56.7 million, and it has announced Medicare Advantage coverage policy for Barostim therapy through Devoted Health. CVRx | Barostim was founded in 2001, has an estimated 200-500 employees, and is headquartered in Minneapolis, Minnesota.
Frequently asked questions
What does CVRx | Barostim do?
CVRx is a publicly listed medical device company headquartered in Minneapolis, Minnesota, founded in 2001 and traded on NASDAQ under the ticker CVRX. It employs between 200 and 500 people and serves the medical and health care sectors. Its flagship product, Barostim, is an implantable system that delivers electrical pulses to baroreceptors in the carotid artery to treat systolic heart failure and resistant hypertension. The company is currently enrolling patients in the BENEFIT-HF trial, which began first patient enrollment in May 2026.
Where is CVRx | Barostim headquartered?
CVRx | Barostim is headquartered in Minneapolis, Minnesota (9201 West Broadway Avenue, Minneapolis, Minnesota, 55445).
When was CVRx | Barostim founded?
CVRx | Barostim was founded in 2001.
How big is CVRx | Barostim?
CVRx | Barostim has an estimated 200-500 employees, with revenue in the 56.7M range.
Is CVRx | Barostim publicly traded?
Publicly traded (NASDAQ: CVRX). Public financial figures are drawn from its filings.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.